Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant melanoma.

J F Smyth

    Cancer Chemotherapy and Biological Response Modifiers
    |January 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Malignant melanoma incidence is rising globally. While surgery is effective for thin melanomas, advanced cases show disappointing results with current treatments, including cytotoxic drugs and early immunotherapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The use of real-world data in cancer drug development.

    European journal of cancer (Oxford, England : 1990)·2018
    Same author

    Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

    Molecular oncology·2016
    Same author

    Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same author

    Growth-control of human ovarian-carcinoma cells by insulin-like growth-factors.

    Oncology reports·2011
    Same author

    Clinically relevant fatigue in recurrence-free prostate cancer survivors.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same journal

    Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    DNA vaccines for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Chemotherapy, cytokines, and biochemotherapy for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Current status of interferon-alpha in the treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    See all related articles

    Area of Science:

    • Dermatology
    • Oncology
    • Immunology

    Background:

    • Rising global incidence of malignant melanoma.
    • Increasing awareness of prognostic factors like tumor thickness and site.
    • Early detection is crucial for effective treatment.

    Purpose of the Study:

    • To review current therapeutic outcomes for malignant melanoma.
    • To assess the efficacy of treatments for advanced melanoma.
    • To evaluate the potential of modern immunotherapy.

    Main Methods:

    • Review of recent annual reports and research findings.
    • Analysis of treatment outcomes for thin and advanced melanoma.
    • Evaluation of cytotoxic drugs and immunotherapies.

    Related Experiment Videos

    Main Results:

    • Surgery remains the primary effective therapy for thin melanoma lesions.
    • Cytotoxic drugs have shown disappointing results in improving survival for advanced melanoma.
    • Modern immunotherapies offer more specificity than older methods, but survival benefits are yet to be proven.

    Conclusions:

    • Effective treatments for advanced malignant melanoma are lacking.
    • Further research is needed to demonstrate the survival benefits of novel immunotherapies.
    • Early detection and surgical intervention are critical for managing thin melanoma.